Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MerLion Pharmaceuticals Pte. Ltd.

www.merlionpharma.com

Latest From MerLion Pharmaceuticals Pte. Ltd.

Antibiotics Pipeline Is Lively, But Sponsors Are Fragile

Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.

Infectious Diseases Clinical Trials

Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome

An FDA advisory committee review of quinolone antibiotic safety focused on a very old safety issue – but points to a new era in antibiotic development, and restricted use models.

MerLion Preps Finafloxacin For Phase III As Advantages Confirmed

Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.

BioPharmaceutical Singapore

ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek

Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.

Dermatology Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • MerLion Pharmaceuticals Pte. Ltd.
  • Senior Management
  • Tony Buss, PhD, Pres. & CEO
    David Dally, CFO
    Martin Everett, PhD, Head, Research
  • Contact Info
  • MerLion Pharmaceuticals Pte. Ltd.
    Phone: (65) 6829 5600
    1 Science Park Rd., The Capricorn #05-01
    , 117528
    Singapore
Advertisement
Advertisement
UsernamePublicRestriction

Register